(Q44841982)

6 December 2017

title

Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open-label trial (English)

1 reference

6 December 2017

0 references

1 reference

1 reference

Javier Arpa

1

1 reference

6 December 2017

Irene Sanz-Gallego

2

1 reference

6 December 2017

Francisco J Rodríguez-de-Rivera

3

1 reference

6 December 2017

Francisco J Domínguez-Melcón

4

1 reference

6 December 2017

Daniel Prefasi

5

1 reference

6 December 2017

Javier Oliva-Navarro

6

1 reference

6 December 2017

Mar Moreno-Yangüela

7

1 reference

6 December 2017

Samuel I Pascual-Pascual

8

1 reference

6 December 2017

publication date

1 October 2013

1 reference

6 December 2017

1 reference

6 December 2017

volume

12

1 reference

6 December 2017

issue

5

1 reference

6 December 2017

page(s)

713-720

1 reference

https://scigraph.springernature.com/pub.10.1007/s12311-013-0482-y

6 December 2017

exact match

0 references

cites work

Clinical and genetic abnormalities in patients with Friedreich's ataxia

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

The natural history of degenerative ataxia: a retrospective study in 466 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Diagnosis and treatment of Friedreich ataxia: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Mortality in Friedreich ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Mapping of the second Friedreich's ataxia (FRDA2) locus to chromosome 9p23-p11: evidence for further locus heterogeneity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Identification of a missense mutation in a Friedreich's ataxia patient: Implications for diagnosis and carrier studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Mutation of the start codon in the FRDA1 gene: linkage analysis of three pedigrees with the ATG to ATT transversion points to a unique common ancestor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Identification of three novel frameshift mutations in patients with Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Pharmacotherapy for Friedreich ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Current and emerging treatment options in the management of Friedreich ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Recombinant human erythropoietin: effects on frataxin expression in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Frataxin interacts functionally with mitochondrial electron transport chain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

SARA--a new clinical scale for the assessment and rating of ataxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Genotype and phenotype analysis of Friedreich's ataxia compound heterozygous patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12311-013-0482-Y

Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)

21 January 2018

1 reference

12 December 2020

Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial

1 reference

12 December 2020

Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features

1 reference

12 December 2020

Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit

1 reference

12 December 2020

Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression

1 reference

12 December 2020

Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin

1 reference

12 December 2020

1 reference

12 December 2020

Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion

1 reference

12 December 2020

Identification of a missense mutation in a Friedreich's ataxia patient: implications for diagnosis and carrier studies

1 reference

12 December 2020

Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia

1 reference

12 December 2020

10.1007/S12311-013-0482-Y

Identifiers

DOI

1 reference

6 December 2017

1 reference